1. Introduction {#sec1-cancers-12-01692}
===============

Cutaneous melanoma is one of the most aggressive metastatic solid tumors, with an increasing incidence over the last decade \[[@B1-cancers-12-01692]\]. Metastatic melanoma is difficult to manage because of its rapid growth and propensity to spread to distant organs such as the liver, lung, and brain \[[@B2-cancers-12-01692]\]. Melanoma has the third highest incidence of brain metastasis of extracranial origin tumors after lung and breast cancers \[[@B3-cancers-12-01692]\]. Melanoma brain metastasis (MBM) can be lethally aggressive although often remains dormant in early stages and clinically undetectable \[[@B4-cancers-12-01692]\]. New effective checkpoint inhibitor immunotherapies (CII) have significantly improved survival outcomes for metastatic melanoma patients \[[@B5-cancers-12-01692],[@B6-cancers-12-01692]\]; however, early detection of MBMs remain a key factor for the implementation of treatment regimens such as: targeted therapy, CII, radiological, and surgical interventions \[[@B5-cancers-12-01692],[@B7-cancers-12-01692]\]. Also, there is still an issue when evaluating which metastatic patients will benefit from specific therapies \[[@B8-cancers-12-01692]\]. Moreover, there is a lack of blood biomarkers available to monitor metastatic melanoma patients undergoing treatment. Until now, elevated serum lactate dehydrogenase (sLDH) levels are the only validated independent diagnostic blood biomarker for the American Joint Committee on Cancer (AJCC) stage IV melanoma patients, but often sLDH does not translate into meaningful clinical information that can be used for deciding patients' therapeutic treatments \[[@B9-cancers-12-01692],[@B10-cancers-12-01692]\].

Blood and urine biomarkers such as cell-free nucleic acids (cfNA) are among the most practical, cost-effective, and minimally invasive approaches that allow for easier compliance and participation by patients \[[@B11-cancers-12-01692],[@B12-cancers-12-01692]\]. As biomarkers, cfNA have limitations in solid tumor patients such as: (1) Detection efficacy as related to the tumor burden, (2) amount of specific tumor cfNA that are detectable in the volume sampled, (3) profiling large numbers of cfNA at one time, and (4) degradation of cfNA \[[@B13-cancers-12-01692],[@B14-cancers-12-01692]\]. Detection of metastatic melanoma has improved in recent years, particularly using circulating cell-free DNA (cfDNA) analysis targeting specific mutations \[[@B15-cancers-12-01692],[@B16-cancers-12-01692],[@B17-cancers-12-01692],[@B18-cancers-12-01692],[@B19-cancers-12-01692]\]. Nonetheless, detection of metastatic cutaneous melanomas has been difficult due to a limited number of frequent mutations that are observed at specific gene exon sites, other than *BRAF* (\<60%) and *NRAS* (\<25%) genes, thus reducing the sensitivity of melanoma detection in blood. Moreover, cfDNA is unstable in body fluids and has a short half-life \[[@B20-cancers-12-01692],[@B21-cancers-12-01692]\].

On the contrary, microRNAs (miRs) are stable short sequence (18--22 nucleotides) regulators that exert post-transcriptional control over gene expression \[[@B22-cancers-12-01692],[@B23-cancers-12-01692]\]. Hanniford et al demonstrated that a 4-miR signature is sufficient to discriminate primary melanoma tumors that will metastasize to the brain from those that will not \[[@B24-cancers-12-01692]\]. Also, specific cfmiRs are found in both serum and plasma of cutaneous melanoma patients as our group and others have demonstrated \[[@B23-cancers-12-01692],[@B25-cancers-12-01692],[@B26-cancers-12-01692],[@B27-cancers-12-01692],[@B28-cancers-12-01692],[@B29-cancers-12-01692],[@B30-cancers-12-01692],[@B31-cancers-12-01692],[@B32-cancers-12-01692],[@B33-cancers-12-01692],[@B34-cancers-12-01692],[@B35-cancers-12-01692],[@B36-cancers-12-01692]\]. Several cfmiRs have been proposed as single biomarkers, or in combination to be used for diagnostic and prognostic assessment of cutaneous melanoma patients \[[@B23-cancers-12-01692],[@B37-cancers-12-01692]\]. Nonetheless, there are concerns that these cfmiRs are non-cancer related and are associated with normal physiological functions and benign diseases \[[@B23-cancers-12-01692],[@B38-cancers-12-01692]\].

The major issues in the application of cfmiR assays are specificity, reproducibility, and accuracy. The main technical concerns of miR assays are: (1) Inconsistencies in study design where the cfmiR signatures have not been validated in matched tissue samples; (2) fluid sampling volume and efficient extraction of these small cfmiRs; (3) reproducibility and robustness; and (4) detection of low level cfmiRs \[[@B23-cancers-12-01692],[@B39-cancers-12-01692],[@B40-cancers-12-01692]\]. To avoid these issues of cfmiR detection, we used a targeted probe, next generation sequencing (NGS)-based platform (HTG EdgeSeq miRNA Whole Transcriptome Assay (WTA), HTG Edge System software Host version 5.3.772.5028 and HTG REVEAL software version 2.0.1, HTG Molecular Diagnostic, Inc. Tucson, AZ, USA). HTG miRNA WTA profiles the expression of 2083 miRs, requires minimal sample input (\<50 µL), has low processing cost, yields high reproducibility, and offers robustness and high accuracy \[[@B24-cancers-12-01692]\]. This platform is based on an extraction-free direct assay that significantly increases the efficiency of capturing low level miRs; therefore reducing data variability introduced by nucleic acid isolation techniques, which is a major problem in cfNA blood assay reproducibility \[[@B24-cancers-12-01692],[@B41-cancers-12-01692],[@B42-cancers-12-01692]\]. More importantly, miRs can be assessed from limited specimen sources.

This study revealed a cfmiR signature found in the plasma of MBM patients, verified in a second MBM cohort, and corroborated in MBM tissues. We demonstrated that the cfmiR signature detected in the MBM patients overlap with the cfmiR found in pre-treatment plasma samples from metastatic melanoma patients receiving CII. CfmiR detection in urine offers a non-invasive body fluid assay that is more logistically practical for patient compliance. Therefore, we have developed a cfmiR assay for evaluating urine to complement the plasma cfmiR assessment of CII-treated melanoma patients. Specific cfmiRs that were upregulated in the plasma were consistently detected in the paired urine samples of CII-treated melanoma patients.

2. Results {#sec2-cancers-12-01692}
==========

2.1. CfmiRs That Differentiate Plasma from Serum in Normal Healthy Donors {#sec2dot1-cancers-12-01692}
-------------------------------------------------------------------------

There are various studies on identifying cfmiRs in cancer patients. However, there are limited analyses published for cfmiR profiling of large cohorts of plasma and serum samples taken from normal healthy donors \[[@B43-cancers-12-01692]\]. Initially, we assessed and compared normal donors' plasma and serum using the HTG miRNA WTA. To determine the reproducibility of the HTG miRNA WTA, normal donors' plasma (Plasma 1, P1, *n* = 48) and serum (Serum 1, S1, *n* = 48) samples were randomly distributed in a 96-well HTG miRNA WTA. Then, serum (Serum 2, S2, *n* = 48) and plasma (Plasma 2, P2, *n* = 48) samples were obtained from the same healthy donors respectively, and analyzed using HTG miRNA WTA ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}A). Using the parsed raw read counts, we performed DESeq2 data normalization using HTG REVEAL software version 2.0.1 and compared S1 to S2. Normal donors' serum samples S1 and S2 showed similar counts distributions and a correlation value of 0.99 ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}B,C). Similar comparison and results were observed for plasma samples (P1 and P2, [Figure 1](#cancers-12-01692-f001){ref-type="fig"}B,C). Also, both normal donors' serum and plasma samples showed high correlation of the cfmiRs expression ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}C). To identify differentially expressed (DE) cfmiRs, normal donors' plasma and serum samples were compared using HTG REVEAL software version 2.0.1. After data normalization and multiple testing corrections (false discovery rate (FDR) *p* \< 0.05), only cfmiRs with a fold-change (FC) of \>1.2 or \<1.2 and count values of \>100 after normalization were included in further analysis. The normal donors' serum (S1 + S2) and plasma (P1 + P2) samples were pooled and evaluated for differences in cfmiR expression. Overall, the cfmiR profiles were similar for serum and plasma samples, respectively ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}D and [Table 1](#cancers-12-01692-t001){ref-type="table"}A,B). Only two cfmiRs showed significant changes in the same serum samples analyzed in duplicates ([Table 1](#cancers-12-01692-t001){ref-type="table"}); while no significant changes were observed for plasma samples analyzed in duplicates. Then, we compared plasma and serum samples. There were 324 DE cfmiRs in plasma compared to serum samples of which 178 were upregulated and 146 were downregulated ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}E,F). Additionally, plasma and serum samples were compared for cfmiRs associated with gender. Plasma samples from males showed 78 DE cfmiRs compared to females, where the majority (89.7% of the total DE cfmiRs) were upregulated in males versus females ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}G). A similar analysis was performed for the comparison in serum samples of both genders. A total of 181 cfmiRs were DE in both genders. While 61 were downregulated, 120 were upregulated in males compared to females ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}H). When considering the top 10 most variable cfmiRs found in plasma, all 10 cfmiRs were upregulated ([Table 2](#cancers-12-01692-t002){ref-type="table"}A). Similar results were observed when considering the top 10 most DE cfmiRs found in serum, where 9 cfmiRs were upregulated ([Table 2](#cancers-12-01692-t002){ref-type="table"}B). Finally, we examined for common cfmiRs consistently changing in plasma and serum samples when comparing males versus females. A total of 53 cfmiRs were consistently changing in serum and plasma ([Table 3](#cancers-12-01692-t003){ref-type="table"}). Of the 53 cfmiRs commonly DE in both comparison, 52 were consistently upregulated in males versus females in both serum and plasma samples ([Figure 1](#cancers-12-01692-f001){ref-type="fig"}I). In summary, the results showed that there were significant differences in plasma and serum cfmiR profiles. There were no significant differences in the cfmiRs profiles analyzed in plasma samples that were run in duplicates demonstrating the robustness and reproducibility of the HTG miRNA WTA. Fewer cfmiRs showed significant differences in gender analysis in plasma compared to serum samples. Subsequent studies on metastatic melanoma patients were performed on plasma because cfmiR detection in serum can be problematic due to clotting event factors that promote the release of miRs from leukocytes and platelets. Also, there is a preferential use of plasma in cfNA clinical assays.

2.2. A CfmiR Signature That Identifies MBM Patients from Normal Healthy Donors' Plasma {#sec2dot2-cancers-12-01692}
--------------------------------------------------------------------------------------

MBMs are one of the most devastating and difficult metastases to treat. Thus, earlier MBM detection, identification of progressive disease, and treatment response are critical to improve overall outcomes. All blood cfmiR analysis from this point on will be referring to plasma samples. Pre-operative samples from MBM patients (MBM-01, *n* = 36, [Table 4](#cancers-12-01692-t004){ref-type="table"}) were assessed to determine cfmiR signatures that could identify the MBM from normal donors' samples (P1, *n* = 48). For MBM and normal donors' comparison, the same exclusion criteria was used to exclude cfmiRs with low detectability and that were not significantly changing (FDR *p* \< 0.05, FC \> 1.2, or \<1.2 and count values \>100 after normalization). The results showed that 164 cfmiRs were significantly DE in MBM patients' compared to normal donors' samples, of which 79.9% (131 of 164) were upregulated, and 20.1% (33 of 164) were downregulated ([Figure 2](#cancers-12-01692-f002){ref-type="fig"}A). In [Figure 2](#cancers-12-01692-f002){ref-type="fig"}B, the top 5 DE cfmiRs with the highest detection level in MBM patients compared to normal donors' samples are shown. Also, the top 10 most DE cfmiRs are shown ([Figure 2](#cancers-12-01692-f002){ref-type="fig"}C).

To verify the cfmiR signature obtained in the first cohort of MBM patients, we assessed a second cohort of MBM patients (MBM-02, *n* = 24, [Table 4](#cancers-12-01692-t004){ref-type="table"}). Pre-operative plasma samples from the second cohort of MBM (*n* = 24) patients were assessed and compared to normal donors' samples (P1, *n* = 48). We observed 166 DE cfmiRs in MBM patients compared to normal donors' samples (FDR *p* \< 0.05, FC \> 1.2, or \<1.2 and count values \>100 after normalization). Of the 166 cfmiRs, 68 were downregulated and 98 were upregulated ([Figure 2](#cancers-12-01692-f002){ref-type="fig"}D). Surprisingly, 74 were consistently changing in both MBM cohorts. While 20 were consistently downregulated, 54 were upregulated ([Figure 2](#cancers-12-01692-f002){ref-type="fig"}E).

To corroborate the origin of the MBM cfmiR signature, we analyzed a cohort of MBM tissues (*n* = 24) and compared the 74 cfmiR profiles commonly changing in the two cohorts of MBM patients' compared to normal donors' samples. We found 16 (21.6%) cfmiRs changing in MBM plasma that 7 were not present in MBM tissues ([Table 5](#cancers-12-01692-t005){ref-type="table"}) and 58 (78.4%) DE cfmiRs in MBM plasma that were consistently expressed in the MBM tissues ([Figure 3](#cancers-12-01692-f003){ref-type="fig"}A). This 58 cfmiR signature was verified to differentiate MBM patients from normal donors' samples using principal component analysis (PCA, [Figure 3](#cancers-12-01692-f003){ref-type="fig"}B). The first five components of the PCA showed 82.5% and 89.1% mean cumulative variance in MBM-01 and MBM-02 respectively ([Table 6](#cancers-12-01692-t006){ref-type="table"}). To determine the association among the cfmiRs identified, the 58 cfmiRs were clustered based on their correlation values. Three main clusters (cluster 1, 2, and 3) were observed in the correlation matrix ([Figure 3](#cancers-12-01692-f003){ref-type="fig"}C, [Table 7](#cancers-12-01692-t007){ref-type="table"}A--C). Moreover, two clusters showed that members of the same family clustered together (i.e. cluster 1: miR-320b and miR-320d, miR-181b-5p and miR-181a-5p, miR-99b-5p and miR-99a-5p; cluster 3: miR-1273a, miR-1273c, miR-1273e, and miR-1273g-5p). To summarize, we identified a 74 cfmiR signature differentiating MBM patients' from normal donors' samples that were consistently present in the MBM tissues analyzed. These results also validated the hypothesis that there is consistency between the cfmiRs observed in the MBM patients' plasma and tumors.

2.3. CfmiRs That Differentiate MBM from Other Brain Tumors {#sec2dot3-cancers-12-01692}
----------------------------------------------------------

We assessed plasma samples from breast cancer brain metastasis (BCBM) and lung cancer brain metastasis (LuBM), and compared them to MBM patients for identification of distinct cfmiR signatures. BCBM (*n* = 7) and LuBM (*n* = 6) patients samples cfmiR profiles were analyzed and compared to those obtained from the MBM plasma samples (MBM-01, *n* = 36). For this analysis the same exclusion criteria were used (FDR *p* \< 0.05, FC \> 1.2 or \<1.2, and count values \>100 after normalization). MBM patients revealed 218 DE cfmiRs compared to BCBM patients ([Figure 4](#cancers-12-01692-f004){ref-type="fig"}A); 35 cfmiR were upregulated and 183 were downregulated in MBM compared to BCBM patients. Similar comparisons were performed in MBM versus LuBM patients. MBM showed that 23 cfmiRs were DE; of these 15 were upregulated and 8 were downregulated ([Figure 4](#cancers-12-01692-f004){ref-type="fig"}B). In summary, 218 and 23 DE cfmiRs were found in the MBM patients when compared to the BCBM and LuBM patients, respectively.

Next, we analyzed for cfmiRs in a cohort of glioblastoma (GBM, *n* = 36) plasma samples. CfmiRs from the first cohort of MBM patients were compared to the cfmiR profiles obtained from the GBM patients. We found that 84 cfmiRs were DE in MBM patients versus GBM patients of which 58 were upregulated and 26 were downregulated ([Figure 4](#cancers-12-01692-f004){ref-type="fig"}C). Through integrated data analysis of the cfmiRs commonly identified as DE between normal donors and MBM (74 DE cfmiRs), BCBM and MBM (218 DE cfmiRs), LuBM and MBM (23 DE cfmiRs), and GBM and MBM (84 DE cfmiRs) plasma samples, only 6 cfmiRs remained commonly DE and detected in all of the comparisons ([Figure 4](#cancers-12-01692-f004){ref-type="fig"}D). These 6 cfmiRs could be used as a potential diagnostic tool to discriminate MBM from LuBM, BCBM, and GBM patients. Then, we searched for cfmiRs that exclusively distinguished MBM patients from normal donors' samples that were not present in LuBM, BCBM, and GBM patients. The initial 74 cfmiRs, identified in both MBM cohorts, were compared with those DE cfmiRs found in the comparisons of all the respective brain tumor types. An exclusive signature of 29 cfmiRs differentiated MBM from the other brain tumors and normal donors ([Figure 4](#cancers-12-01692-f004){ref-type="fig"}E and [Table 8](#cancers-12-01692-t008){ref-type="table"}). This 6 cfmiR signature combined with a 29 specific cfmiR signature found in MBM plasma samples may potentially allow for the assessment of melanoma patients developing MBM. More samples are needed to be analyzed in future studies to validate our conclusions.

2.4. CfmiR in Patients Treated with Checkpoint Inhibitor Immunotherapy {#sec2dot4-cancers-12-01692}
----------------------------------------------------------------------

CII has become the standard of care for metastatic melanoma patients in the last several years and has improved survival outcomes \[[@B8-cancers-12-01692]\]. However, monitoring patients to determine their treatment response remains a major problem. To identify specific cfmiR signatures, in plasma and urine samples from pre- and post-CII-treated melanoma patients ([Table 9](#cancers-12-01692-t009){ref-type="table"}) were assessed using the HTG miRNA WTA. Plasma samples obtained from both pre- and post-treatment groups were compared to normal donors' samples. We identified 219 and 228 cfmiRs as DE in pre- and post-treatment CII patients compared to normal donors' samples, respectively ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}A). A total of 196 cfmiRs were consistently changing in pre- and post-treatment samples. 18 cfmiRs showed a decrease in expression levels, while 178 cfmiRs showed an increase when compared to the normal donors' samples ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}B). It should be noted that 89.5% of cfmiRs were consistently up or downregulated in the pre- and post-treatment paired samples, respectively. Only 10.5% (22 of 219) of cfmiRs that were detected in pre-treatment samples were not significantly changing in post-treatment samples (data not shown). Also, 8 DE cfmiRs identified in pre- and post-treatment samples were also detected in MBMs but not in other brain cancer metastasis or primary brain tumors ([Table 10](#cancers-12-01692-t010){ref-type="table"}).

It still remains unknown whether these cfmiRs relate to the clinical course of the disease and if they can be used to monitor a patients' response to CII-treatment. CfmiRs may be applied to detect immune-related adverse events (IRAE) pre-symptomatically, however, further studies are needed to test this hypothesis.

Consistently, 22.9% (8 of 35) of the DE cfmiRs identified in the two MBM cohorts were also found to be enhanced in the pre-treatment samples of metastatic CII patients ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}C). To summarize, specific cfmiRs are detectable in pre- and post-treatment samples of CII patients. Also, 8 of the 35 cfmiRs MBM signature overlapped with pre-treatment samples of melanoma patients receiving CII.

2.5. CfmiR in Urine {#sec2dot5-cancers-12-01692}
-------------------

CfmiRs in the blood are filtered by the kidney and excreted from the body in the urine. Since the cfmiRs found in the urine are generally diluted, we developed a novel isolation assay to purify and concentrate the cfNA from 15 mL of urine (see Materials and Methods). cfNAs isolated from urine were analyzed using HTG miRNA WTA. Initially, we assessed urine cfmiRs from normal healthy donors (*n* = 8) in duplicates demonstrating reproducibility. The analysis demonstrated that 251 cfmiRs were detected in normal donors' urine samples using the same cutoff conditions as established for plasma analysis ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}D). 55% (138 of 251) of the cfmiRs detected in normal donors' urine samples were also present in normal donors' plasma samples ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}D). Of note, the urine and plasma samples were not isolated from the same patients in these studies.

On establishment of the urine cfmiR assay, we then analyzed the urine collected from 14 metastatic melanoma patients ([Table 9](#cancers-12-01692-t009){ref-type="table"}). Normal donors' urine samples were then compared with pre- and post-treatment urine samples collected from melanoma patients receiving CII. In this analysis 96 cfmiRs were DE in pre-treatment compared to normal donors' urine samples; while 93 cfmiRs were observed in post-treatment urine samples when compared to normal donors' urine samples ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}E). In both pre- and post-treatment, 77 cfmiRs were consistently DE ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}F).

In order to determine cfmiRs consistently detected in plasma and urine, 11 metastatic melanoma patients with paired pre-treatment plasma and urine samples were compared. Consistently, 7 cfmiRs were increased in the pre-treatment plasma and urine samples ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}G). Of these 7 cfmiRs, 3 cfmiRs (miR-6796-3p, miR-7114-3p, and miR-1207-5p) were also observed in the 58 cfmiRs detected in MBM plasma and tissues samples and in the 35 cfmiR signature proposed. Surprisingly, miR-7114-3p and miR-1207-5p were also detected in post-treatment plasma ([Table 10](#cancers-12-01692-t010){ref-type="table"}). Receiver operating characteristic (ROC) curve for the 35 cfmiR signature detected in MBM. Optimal balance between sensitivity (86.7%) and specificity (83.3%) (Area under the ROC curve (AUC) 0.911, 95% CI: 0.855 -- 0.966, *p* \< 0.001) at 10 cfmiR as a cutoff value ([Figure 5](#cancers-12-01692-f005){ref-type="fig"}H).

3. Discussion {#sec3-cancers-12-01692}
=============

Recently cfNA assays have shown promising utility as blood cancer biomarkers particularly when compared to other types of blood cancer biomarkers such as proteins and circulating tumor cells \[[@B1-cancers-12-01692],[@B20-cancers-12-01692],[@B23-cancers-12-01692],[@B39-cancers-12-01692],[@B40-cancers-12-01692],[@B44-cancers-12-01692],[@B45-cancers-12-01692],[@B46-cancers-12-01692],[@B47-cancers-12-01692],[@B48-cancers-12-01692]\]. Many cfNA cancer assays have been Food and Drug Administration (FDA) and Clinical Laboratory Improvement Amendments (CLIA) approved for deciding different cancers' treatment implementation in the USA and Europe. However, there are still limitations and concerns associated with cfDNA such as the isolation, assay sensitivity, multiple profiling, analytics, and degradation. All of these factors can affect the final results' interpretation \[[@B14-cancers-12-01692],[@B39-cancers-12-01692],[@B40-cancers-12-01692]\]. To overcome these issues, we utilized a modified HTG miRNA WTA to successfully assess cfmiR found in the plasma and urine samples from cancer patients.

Our results demonstrated the robustness of the HTG miRNA WTA in detecting cfmiRs in both serum, plasma, and urine samples. The comparison between normal donors' serum and plasma demonstrated differences in 324 cfmiRs. There are various explanations for this observation, as other groups have shown and discussed previously \[[@B14-cancers-12-01692],[@B39-cancers-12-01692],[@B40-cancers-12-01692],[@B44-cancers-12-01692],[@B45-cancers-12-01692]\]. The limitation in serum analysis is the miRs contamination during blood clotting \[[@B39-cancers-12-01692],[@B40-cancers-12-01692]\]. Differences between serum and plasma could be linked to the presence of extracellular vesicles containing high levels of miRs in the serum \[[@B49-cancers-12-01692]\]. In general, plasma has become the standard blood fluid analytic source for cfNA assays in cancer patient analysis. Our results showed a higher reproducibility in plasma compared to serum, and reduced variability in gender comparisons in plasma.

A 74 cfmiR signature was detected in two MBM patient plasma cohorts when compared to normal donors' plasma. Only 58 cfmiRs were consistently detected in MBM tissues. The better explanation for this discrepancy between cfmiRs in MBM patients' plasma and tumor tissue may arise from differences in the cfmiRs released from the tumor microenvironment, absorption from tumor adjacent normal cells, dilution effect in blood, and filtrations in different organs. Tumor microenvironment contains cells such as immune cells, supporting stroma cells, and/or activated normal brain tissue cells that may account for the release of cfmiRs during brain tumor establishment and progression \[[@B36-cancers-12-01692],[@B50-cancers-12-01692]\].

In the cfmiR comparisons of MBM versus other extracranial origin brain cancer metastasis and GBM, we refined and selected a 6 and 29 cfmiR signature, respectively. The former signature pattern has a potential screening utility to distinguish MBM from other brain metastasis of common tumors and GBM. This signature may have utility in screening patients with brain tumors with an unknown primary tumor. The 29 cfmiR signature in combination with the 6 cfmiR signature may be utilized to monitor MBM patients post-surgery for early disease progression. However, further validation is required for the second signature in an independent cohort of BCBM, LuBM, and GBM patients.

The 35 cfmiR signature identified in MBM were also assessed in pre- and post-treatment plasma samples taken from melanoma patients receiving CII. Interestingly, 8 DE cfmiRs that were exclusively detected in MBM plasma were also detected in the pre- and post-treatment plasma of patients receiving CII. Further validation in a larger independent cohort of melanoma patients receiving CII, with serial blood samples, and Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) evaluation will be needed in future studies. Successful detection of early progression of CII-treated patients, who have failed treatment, and/or develop MBM will be an important real-time blood diagnostic tool to assist in making treatment decisions for patients.

Urine is an alternative non-invasive body fluid source for assessing cfmiRs. There are several advantages associated with urine-based assays: (1) Non-invasive procedures, (2) can be repetitively monitored, (3) easier compliance by patients, and (4) larger volumes of fluids can be obtained \[[@B11-cancers-12-01692]\]. The procurement of large volumes of blood from CII patients for clinical tests and research purposes is not always feasible. This issue is more prevalent in older patients and in patients who have difficulty having routine blood samples drawn. Conversely, a limitation for cfmiR assessment in urine is the detection of representative cfmiRs derived from tumor cells. Usually cfmiR present in the urine represents those present at high levels in the blood. Many cfmiRs may be filtered out in the kidneys and eventually destroyed in the urine due to pH and other physiological aspects of urine such as metabolic contaminants in urine. Other factors known to influence clinical testing of urine biomarker detection include diurnal fluctuations, time of void collections as related to fluid intake or diuretics, cancer drug treatment, age, etc. Further technical and logistical developments will improve cfmiRs detection in urine.

Previous studies have identified cfmiRs in different body fluids and have demonstrated how they are distributed \[[@B51-cancers-12-01692],[@B52-cancers-12-01692],[@B53-cancers-12-01692]\]. Ashish et al isolated and sequenced total extracellular RNA from 183 plasma samples, 204 urine samples, and 46 saliva samples from 55 healthy donors, and found that 84 out of 92 miRNAs detected in urine samples were also detected in plasma samples \[[@B51-cancers-12-01692]\]. Our urine analysis showed a similar number of cfmiR detected when compared to plasma. In the present study, we showed that specific cfmiRs identified in the MBM plasma were also detected in the pre- and post-treatment plasma samples from patients receiving CII, and consistently detected in the paired urine samples.

The urine studies demonstrated the potential utility of the assays to detect cfmiRs in pre- and post-treatment plasma samples from metastatic melanoma patients that may be associated to CII patients' status. Further studies are needed to increase the sample size and to validate our findings. This study is novel compared to previous studies published in the field of non-urological cancer detection because of: (1) The detection of signatures instead of single biomarkers, (2) the low volumes of blood (\<50 µL) required for using a direct assay, (3) the assay relies on an NGS-based platform providing high specificity, (4) the several verification steps that have been included to obtain reproducible cfmiR signatures, and (5) the development of a urine assay enabling cfmiR assessment from melanoma patients. Hence, these findings can be translated into a diagnostic assay for cfmiR monitoring of metastatic melanoma patients.

4. Materials and Methods {#sec4-cancers-12-01692}
========================

4.1. Consent to Participate and Patient Specimen Accrual {#sec4dot1-cancers-12-01692}
--------------------------------------------------------

This pilot study followed the principles in the Declaration of Helsinki. All human samples and clinical information for this study were obtained according to the protocol guidelines approved by the Saint John's Health Center (SJHC)/John Wayne Cancer Institute (JWCI) Joint Institutional Review Board (IRB): JWCI Universal Consent (Providence Health System Portland IRB: JWCI-18-0401) and Western IRB: MORD-RTPCR-0995. Informed consent was obtained from all participants.

### 4.1.1. Blood and Urine {#sec4dot1dot1-cancers-12-01692}

Blood samples of healthy donors and cancer patients were obtained at SJHC/JWCI. Blood samples were accrued and processed to obtain serum or plasma. Briefly, all blood samples that were used for plasma isolation were collected in Streck tubes (Streck, La Vista, NE, USA), processed, aliquoted, barcoded, and cryopreserved at −80 °C as previously described \[[@B15-cancers-12-01692]\]. Blood samples that were used for serum isolation were collected in BD Vacutainer® Venous Blood Collection Tubes, BD Diagnostics (VWR, Radnor, PA, USA) and allowed to clot at RT for 1--3 hours, centrifuged, processed as serum, filtered for cell contamination, and cryopreserved at −80 °C as previously described \[[@B15-cancers-12-01692]\]. Aliquots of serum or plasma were thawed only once and mixed, before being analyzed for miR profiling by HTG miRNA WTA. Serum (*n* = 48) and plasma (*n* = 48) were collected from normal healthy donors ranging in age from 21--65 years old and were analyzed twice using HTG miRNA WTA. Single pre-operative blood samples from MBM (*n* = 36, first cohort), MBM (*n* = 24, second cohort), GBM (*n* = 36), BCBM (*n* = 7), and LuBM (*n* = 6) were collected and analyzed using HTG miRNA WTA. Pre- and post-treatment plasma samples from metastatic cutaneous melanoma CII-treated (*n* = 20) patients were also collected and analyzed using HTG miRNA WTA.

Urine samples from healthy donors (*n* = 8) and melanoma patients with paired pre- (*n* = 14) and post-treatment (*n* = 14) urine samples were collected and processed for miR NGS detection as described in [Section 4.2.5](#sec4dot2dot5-cancers-12-01692){ref-type="sec"}. Urine samples were collected using a standard sterile 100 mL urine collection cup (Medtronic, Minneapolis, MN, USA). Each urine cup contained Ethylenediamine tetraacetic acid (EDTA) 0.05M pH 8.0 (Bioworld, Little Rock, AR, USA). Total DNA/RNA (\~139 ng) was extracted from a 15 mL urine sample using the urine nucleic acid isolation kits and the automated nucleic acid isolation system (JBS Science, Inc., Doylestown, PA, USA). The isolated nucleic acids in elution buffer were then aliquoted and cryostored in a −80 °C freezer until needed for assays.

Eleven patients' paired urine and blood samples were collected prospectively from melanoma patients. CII treatment responses were assessed at every patient follow-up visit at the cancer clinic as recommended as the standard treatment for the FDA-approved CII drugs (Ipilimumab, Nivolimumab, and Pembrolizumab) \[[@B15-cancers-12-01692]\]. Briefly, computerized tomography/magnetic resonance imaging was assessed every three months according to the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST), denoting progressive disease (PD), stable disease (SD), partial response (PR), complete response (CR), or no evidence of disease (NED). This study was performed in accordance with the Reporting recommendations for tumour marker (REMARK) guidelines \[[@B54-cancers-12-01692],[@B55-cancers-12-01692]\]. The clinical demographics of the melanoma patients analyzed are summarized in [Table 4](#cancers-12-01692-t004){ref-type="table"} and [Table 9](#cancers-12-01692-t009){ref-type="table"}.

### 4.1.2. MBM FFPE Tissues {#sec4dot1dot2-cancers-12-01692}

MBM tissues were obtained from elective surgeries performed at SJHC. Formalin-fixed paraffin-embedded (FFPE) tissues from MBM patients (*n* = 24) were obtained for HTG miRNA WTA. FFPE MBM tissue sections were cut into 5 µm sections and the tumor areas were micro-dissected with sterile scalpels and dissection needles. Hematoxylin and Eosin (H&E) stained slides marked by a surgical pathologist were used as a guide to determine the area of interest and to avoid including any normal, non-tumor, or necrotic tissue. The tumor tissue section, as determined by H&E, was measured for its total surface area. FFPE tissue sections of approximately 10 mm^2^ were required; multiple slides were micro-dissected for tissue sections less than 10 mm^2^. Sections with tumor tissues exceeding a surface area of 10 mm^2^ were scraped entirely into their respective tubes. Stained H&E slides were overlaid with the unstained slides and then used as templates for micro-dissection. Micro-dissected tissues were processed as described in [Section 4.2.3](#sec4dot2dot3-cancers-12-01692){ref-type="sec"}.

4.2. Sample Processing for HTG miRNA WTA {#sec4dot2-cancers-12-01692}
----------------------------------------

For normal donors' serum/plasma controls, processing and library preparation were performed as described in [Section 4.2.1](#sec4dot2dot1-cancers-12-01692){ref-type="sec"} and [Section 4.2.2](#sec4dot2dot2-cancers-12-01692){ref-type="sec"}. For tissue analysis, the samples were processed as described in [Section 4.2.3](#sec4dot2dot3-cancers-12-01692){ref-type="sec"} and [Section 4.2.4](#sec4dot2dot4-cancers-12-01692){ref-type="sec"}. Urine processing and library preparation were performed as described in [Section 4.2.5](#sec4dot2dot5-cancers-12-01692){ref-type="sec"}.

### 4.2.1. Serum and Plasma Processing for HTG miRNA WTA {#sec4dot2dot1-cancers-12-01692}

Normal donors' controls and cancer patients' serum and plasma samples were thawed, mixed, and analyzed using the HTG miRNA WTA following the manufactures' recommendations. Serum/plasma (30 µL) were lysed with HTG Biofluids buffer or Plasma Lysis buffer, respectively with Proteinase K (HTG Molecular Diagnostics Inc., Tucson, AZ, USA). Lysed samples were incubated on a heat block at 50 °C for three hours and each hour the samples were mixed by pipetting. Lysed samples were then processed on the automated HTG EdgeSeq instrument for probe-capture of 2083 validated human miRs for 20 hours. After probe-capture, the samples were processed for NGS library preparation.

### 4.2.2. Serum and Plasma Library Preparation {#sec4dot2dot2-cancers-12-01692}

Probe-captured miR samples were then amplified and indexed via polymerase chain reaction (PCR) using master mix (10 mM deoxyribonucleotide triphosphate (dNTP) 5× Hemo Klentaq® Reaction buffer, Hemo Klentaq® DNA polymerase (New England Biolabs Inc., Ipswich, MA, USA), forward, and reverse primers (HTG Molecular Diagnostics Inc., Tucson, AZ, USA)). The PCR conditions for the reactions were: (1) 95 °C for 4 min, (2) 95 °C for 15 s, (3) 56 °C for 45 s, (4) 68 °C for 45 s, (5) repeat steps 2--4 for 16 total cycles, (6) 68 °C for 10 min, and (7) hold at 4 °C. Following PCR, library cleanup was performed using Ampure^®^ XP beads (Beckman Coulter Inc., Brea, CA, USA). The samples were mixed and incubated with the beads at room temperature (RT) for 5 min. The bead-bound libraries were then washed twice with 80% ethanol to remove any leftover PCR reagents and enzymes. After washing, the samples were dried at RT for 2 min to allow the residual ethanol to evaporate. The libraries were then eluted off the beads with 10 mM Tris hydrochloride (Tris-HCl), pH 8.0.

### 4.2.3. MBM Tissue Processing for HTG miRNA WTA {#sec4dot2dot3-cancers-12-01692}

Micro-dissected FFPE tissues were digested in a calculated volume of HTG Lysis buffer equaling 25 µL of Lysis buffer per 10 mm^2^ of total target tissue. HTG denaturation oil was then overlaid on top of each FFPE-Lysis buffer sample. Samples were incubated at 95 °C for 15 min to denature protein structures and remove paraffin wax from the FFPE tissue sections. Samples were cooled down for 10 min at RT and an HTG-provided Proteinase K was pipetted into the aqueous (lysis, non-oil) phase of the samples at a volume 1/20th of the total lysis buffer. The samples were finally incubated at 50 °C for three hours, mixing the aqueous phase by pipetting every hour before loading 25 µL of the sample lysate onto the HTG EdgeSeq instrument for miR probe-capture.

### 4.2.4. MBM Tissue Library Preparation {#sec4dot2dot4-cancers-12-01692}

Probe-captured MBM FFPE miR samples were then amplified and indexed via PCR using the master mix (One*Taq* HotStart 2X MasterMix in GC Buffer (New England Biolabs Inc., Ipswich, MA, USA), with forward and reverse primers. PCR conditions were as described in [Section 4.2.2](#sec4dot2dot2-cancers-12-01692){ref-type="sec"}. Library cleanup was performed by adding a Clean Up buffer (39% 5M NaCl, 31.25% of 40% PEG 8000, 29.75% molecular-grade water) to AMPure XP beads before combining it with the PCR-amplified sample. Ethanol washing and sample eluting were performed as described above in [Section 4.2.2](#sec4dot2dot2-cancers-12-01692){ref-type="sec"}.

### 4.2.5. MBM Urine Processing for HTG miRNA WTA {#sec4dot2dot5-cancers-12-01692}

After nucleic acid isolation from melanoma patients' urine samples (refer to [Section 4.1.1](#sec4dot1dot1-cancers-12-01692){ref-type="sec"}), 35 ng of RNA was loaded onto the HTG EdgeSeq instrument for WTA probe-capture. Samples were diluted in HTG Lysis buffer or BioFluids Lysis buffer according to the manufacturer's recommendations. Library preparation and cleanup were as described in [Section 4.2.4](#sec4dot2dot4-cancers-12-01692){ref-type="sec"}.

### 4.2.6. NGS Library Quality Check {#sec4dot2dot6-cancers-12-01692}

All libraries were quantitated using the KAPA Library Quant Kit (Illumina Inc., San Diego, CA, USA) and the Universal qPCR Mix Kit (Roche, Basel, Switzerland) according to the manufacturer's recommendations. Quality check (QC) for library size was performed on the Agilent Technologies TapeStation 2200 instrument using the High Sensitivity D1000 ScreenTape and High Sensitivity D1000 reagents (Agilent Technologies Inc., Santa Clara, CA, USA). The expected peak size was between 150 and 170 base pairs. Samples that did not indicate proper library formation were excluded from sequencing and repeated for library preparation.

### 4.2.7. NGS Library Normalization and Pooling {#sec4dot2dot7-cancers-12-01692}

Quantitated libraries were diluted, normalized, and pooled according to the protocol generated by the HTG EdgeSeq RUO Library calculator software version 2.0.0. Libraries were denatured in 2 N NaOH for 8 min at RT. NaOH was hydrolyzed with 2 N HCl and the denatured pool was diluted down to 20 pM with the HT1 buffer supplied in the MiSeq V3 Kit (Illumina Inc., San Diego, CA, USA). To introduce sequencing diversity and a positive sequencing control, 12.5 pM PhiX Control v3 library (Illumina Inc., San Diego, CA, USA) was spiked into the diluted and denatured 20 pM sample pool. The final pool was made to be 95% sample libraries and 5% PhiX control by concentration. The pooled library was then denatured at 98 °C for 4 min and immediately placed on ice for at least 5 min before loading it onto the Illumina HiSeq 2500, MiSeq, or NextSeq 550 instruments according to the respective Illumina instrument sequencing protocols.

### 4.2.8. NGS Profiling of the Libraries {#sec4dot2dot8-cancers-12-01692}

Sequencing with Illumina platforms was conducted according to HTG instructions. Sequences were assessed with a read length of 1 × 50 base pairs. FASTQ files were generated from raw sequencing data using Illumina BaseSpace BCL to FASTQ software version 2.2.0 and Illumina Local Run Manager Software version 2.0.0. FASTQ files were analyzed with HTG EdgeSeq Parser software version v5.1.724.4793 to generate raw counts for 2083 miRs per sample.

### 4.2.9. HTG NGS Arrays {#sec4dot2dot9-cancers-12-01692}

The HTG miRNA WTA was run on a 96-well HTG plate configuration for the normal donors' plasma and serum samples, while the melanoma patients' plasma samples were run on a 24-well HTG plate configuration. Each HTG miRNA WTA includes negative (CTRL_ANT1, CTRL_ANT2, CTRL_ANT3, CTRL_ANT4, CTRL_ANT5) and positive (CTRL_miR_POS) miR controls that are included in the 2083 total miR panel. In all runs, Human Brain Total RNA (Ambion, Inc., Austin, TX, USA) was used as a control for library preparation, but they were not sequenced. To test the reproducibility of the HTG miRNA WTA, the normal donors' plasma and serum patients' samples were run twice on the HTG EdgeSeq instrument and subsequently sequenced to check for reproducible results.

4.3. Biostatistical Analysis {#sec4dot3-cancers-12-01692}
----------------------------

The DESeq2 data subgroup normalization, analyses, and statistical comparisons in: (1) Normal serum versus normal donors' plasma; (2) MBM-01 plasma versus normal donors' plasma; (3) MBM-02 versus normal donors' plasma; (4) MBM01-02 plasma versus MBM tissue; (5) MBM-01 plasma versus LuBM plasma; (6) MBM-01 plasma versus BCBM plasma; (7) MBM-01 plasma versus GBM plasma; and (8) melanoma CII-treated pre- and post-treatment plasma versus normal donors' plasma; (9) melanoma CII-treated pre- and post-treatment urine versus normal donors' urine were all performed using the HTG REVEAL software version: 2.0.1. Box plot and t-test analysis were performed with GraphPad prism 5 (GraphPad software Inc., La Jolla, CA, USA). Data processing and analysis were performed using Python 3.7.4 in Jupyter platform \[[@B56-cancers-12-01692]\]. MicroRNA expression counts were logarithmically scaled (log~10~) for data visualization. PCA and data normalization were performed using Scikit-learn open source Python library version 0.22.1 \[[@B57-cancers-12-01692]\] to signify miRNA expression profiles. Matplotlib package version 3.1.3 was utilized for making 2D plots in the python environment \[[@B58-cancers-12-01692]\]. Hierarchically clustered heatmaps were generated using Seaborn version 0.10.1. NumPy library version 1.18.1 \[[@B59-cancers-12-01692]\] and SciPy library 1.4.1 version \[[@B60-cancers-12-01692]\] were utilized to process data matrices. AUC calculation was performed with the SPSS software program, ver. 25.0 (IBM Inc., Chicago, IL, USA). A two-sided *p*-value \< 0.05 was considered statistically significant: \* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001 and NS = non-significant. The figures were made using CorelDraw graphics suite 8X (Corel Corporation, Ottawa, ON, Canada).

4.4. Data Deposit {#sec4dot4-cancers-12-01692}
-----------------

The data generated and discussed in this pilot study has been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and is accessible through the GEO Series accession number GSE150956.

5. Conclusions {#sec5-cancers-12-01692}
==============

There is an urgent need to identify robust cfmiR biomarkers that are detectable in body fluid biopsy assays. We have provided a comprehensive analysis (Graphical abstract) using different cohorts of MBM, LuBM, BCBM, and GBM tumors. The results demonstrated how specific cfmiR signatures distinguished MBMs from other types of brain cancer metastases as well as primary GBMs. Moreover, cfmiR detection can potentially be used to monitor melanoma patients undergoing CII therapy. Specific cfmiRs identified in MBMs overlapped with melanoma patients receiving CII. A urine cfmiR assay was developed to demonstrate the detection of cfmiRs and its potential in assessing melanoma patients receiving CII. Our results showed the potential utility of the HTG miRNA WTA and the cfmiR signatures detected in plasma and urine samples for monitoring metastatic melanoma patients' progression and treatment.
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![Comparison of serum and plasma samples from normal healthy donors. (**A**) Schematic representation of the samples analyzed throughout the study. (**B**) Cell-free microRNAs (cfmiRs) normalized counts distribution in serum (S1-S2) and plasma (P1-P2) samples for the first (S1 and P1) and second sequencing assays (S2 and P2) respectively. (**C**) Correlation matrix of cfmiRs analyzed in serum (S1-S2) and plasma (P1-P2) samples for the first (S1 and P1) and second sequencing assays (S2 and P2) respectively. (**D**) Heatmap showing the normalized counts of cfmiRs observed in plasma (P1-P2) and serum (S1-S2) respectively. (**E**) Heatmap showing the cfmiRs significantly changing in plasma compared to serum samples. (**F**) Differentially expressed (DE) cfmiRs in plasma versus serum samples. (**G**,**H**) DE cfmiRs in males versus females observed in plasma (**G**) and serum (**H**) samples, respectively. (**I**) Commonly DE cfmiRs in males versus females in serum and plasma samples.](cancers-12-01692-g001){#cancers-12-01692-f001}

![Differentially expressed (DE) cell-free microRNAs (cfmiRs) in serum versus plasma from normal healthy donors' samples. (**A**) Schematic of the cfmiRs DE, either up- or down-regulated in the plasma of melanoma brain metastasis first cohort (MBM-01) patients compared to the normal donors' samples. (**B**) Boxplots showing the top 5 DE cfmiRs with the highest detection levels in MBM-01 patients compared to normal donors' samples (\*\*\* *p* \< 0.001). (**C**) Boxplots showing the top 10 most DE cfmiR in MBM-01 patients compared to normal donors' samples (\*\*\* *p* \< 0.001). (**D**) Schematic of the cfmiRs DE, either up- or down-regulated in the plasma of melanoma brain metastasis second cohort (MBM-02) patients compared to the normal donors' samples. (**E**) Comparison of the DE cfmiRs and changing inconsistently or consistently in MBM-01 and MBM-02 patients' cohorts.](cancers-12-01692-g002){#cancers-12-01692-f002}

![A Cell-free microRNA (cfmiR) signature in the plasma that differentiates melanoma brain metastasis (MBM) patients' from normal donors' samples. (**A**) Scheme of the differentially expressed (DE) cfmiRs in MBM patients compared to normal donors' samples that were detected in MBM tissue samples. (**B**) Principal component analysis (PCA) analysis of the 58 DE cfmiRs in MBM-01 (left) or MBM-02 (right) patients versus normal donors' samples that were also present in the MBM tissues. (**C**) Clustering of the 58 cfmiRs that differentiate MBM patients from normal donors' samples. Three clusters were identified: cluster 1 (pink), cluster 2 (green), and cluster 3 (blue).](cancers-12-01692-g003){#cancers-12-01692-f003}

![Cell-free microRNAs (cfmiRs) that differentiate melanoma brain metastasis (MBM) patients from extracranial cancer brain metastasis and glioblastoma (GBM) patients. (**A**,**B**) Schematic summary of the cfmiRs identified in MBM vs. breast cancer brain metastasis (BCBM) (**A**), MBM vs. lung cancer brain metastasis (LuBM), (**B**), MBM vs. GBM (**C**). (**D**) A 6 cfmiR signature was identified after comparisons of MBM vs. normal donors to MBM vs. BCBM, MBM vs. LuBM, and MBM vs. GBM plasma samples as summarized in the Table. (**E**) A 29 cfmiR signature was able to distinguish MBM from other primary and metastatic brain tumors. For details on the cfmiRs identified refer to [Table 8](#cancers-12-01692-t008){ref-type="table"}.](cancers-12-01692-g004){#cancers-12-01692-f004}

![Cell- free miRNA (cfmiR) signatures in urine and plasma of melanoma patients receiving checkpoint immune inhibitor (CII). (**A**) Scheme of the differentially expressed (DE) cell-free microRNAs (cfmiRs) in pre- (left) and post-treatment (right) plasma samples compared to normal donors' plasma samples. (**B**) CfmiRs detected in plasma samples from pre- and post-treatment melanoma patients receiving CII that were inconsistently or consistently changing. (**C**) Comparison of the 35 cfmiRs melanoma brain metastasis (MBM) signature with the cfmiRs detected in pre-treatment CII plasma samples. (**D**) CfmiRs identified in normal donors' urine, plasma, or found in both. (**E**) DE cfmiRs detected in urine samples from pre- (left) and post-treatment (right) melanoma patients receiving CII. (**F**) CfmiRs detected in urine samples from pre- and post-treatment melanoma patients receiving CII that were inconsistently or consistently changing. (**G**) DE cfmiRs that were inconsistently and consistently changing in pre-treatment plasma (left) and urine (right) from melanoma patients receiving CII compared to normal plasma and urine respectively. (**H**) Receiver operating characteristic (ROC) curves for the 35 cfmiRs DE in MBM and the associated areas under curves (AUCs).](cancers-12-01692-g005){#cancers-12-01692-f005}

cancers-12-01692-t001_Table 1

###### 

DE cfmiRs in the plasma (P1 vs. P2) and serum (S1 vs. S2) samples of normal donors.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(A\) Top 10 DE cfmiRs expressed in duplicated plasma samples P1 and P2                                                                                     
  -------------------------------------------------------------------------- ---------------------- ---------------------- ------------------ --------------- ------------------------
  miR-6873-3p                                                                99                     133                    1.21               0.030           0.999

  miR-92b-3p                                                                 269                    369                    1.17               0.081           0.999

  miR-1273e                                                                  350                    454                    1.16               0.09            0.999

  miR-4274                                                                   120                    109                    −1.09              0.138           0.999

  miR-1909-5p                                                                144                    163                    1.11               0.142           0.999

  miR-584-5p                                                                 103                    141                    1.14               0.147           0.999

  miR-3157-5p                                                                101                    115                    1.1                0.179           0.999

  miR-6852-3p                                                                95                     115                    1.12               0.185           0.999

  miR-572                                                                    171                    192                    1.1                0.187           0.999

  miR-1287-5p                                                                371                    430                    1.11               0.190           0.999

  **(B) Top 10 DE cfmiRs expressed in duplicated serum samples S1 and S2**                                                                                    

  **Probe**                                                                  **Mean Normalized**\   **Mean Normalized**\   **FC S1 vs. S2**   ***p*-Value**   **Adjusted *p*-Value**
                                                                             **Expression S1**      **Expression S2**                                         

  miR-6819-5p                                                                149                    103                    1.36               0.0001          0.027

  miR-670-3p                                                                 189                    123                    1.39               0.0001          0.030

  miR-1303                                                                   181                    118                    1.37               0.000           0.064

  miR-1273e                                                                  2776                   2058                   1.26               0.009           0.418

  miR-193a-5p                                                                117                    89                     1.24               0.012           0.478

  miR-1290                                                                   229                    160                    1.26               0.017           0.555

  miR-1299                                                                   527                    381                    1.25               0.023           0.562

  miR-4769-3p                                                                120                    102                    1.15               0.027           0.588

  miR-6852-5p                                                                106                    121                    −1.13              0.028           0.588

  miR-3674                                                                   473                    357                    1.21               0.048           0.703
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DE = differentially expressed. CfmiRs = cell-free microRNAs. FC = fold-change. P1 = plasma 1. P2 = plasma 2. S1 = serum 1. S2 = serum 2. Highlighted in gray are the cfmiRs that were DE in serum samples.

cancers-12-01692-t002_Table 2

###### 

The top 10 DE cfmiRs in male (M) versus female (F) in normal donors' plasma (A) and serum (B) samples.

  \(A\) Plasma   \(B\) Serum                                         
  -------------- ------------- --------------- ------------- ------- ---------------
  miR-451a       2.29          2.94 × 10^−5^   miR-143-5p    1.34    1.50 × 10^−3^
  miR-150-5p     1.84          1.10 × 10^−3^   miR-3943      1.45    2.20 × 10^−3^
  miR-6796-3p    1.45          1.90 × 10^−3^   miR-8071      1.45    2.80 × 10^−3^
  miR-4726-3p    1.37          2.00 × 10^−3^   miR-4746-5p   1.38    3.30 × 10^−3^
  miR-3940-5p    1.59          2.00 × 10^−3^   miR-217       1.38    3.30 × 10^−3^
  miR-3155b      1.42          2.10 × 10^−3^   miR-4758-5p   −1.33   4.40 × 10^−3^
  miR-6798-5p    1.61          2.10 × 10^−3^   miR-6787-5p   1.38    4.40 × 10^−3^
  miR-486-5p     1.70          2.10 × 10^−3^   miR-34b-3p    1.34    5.20 × 10^−3^
  miR-3912-5p    1.39          2.50 × 10^−3^   miR-4522      1.42    5.20 × 10^−3^
  miR-6789-3p    1.30          2.70 × 10^−3^   miR-193a-3p   1.43    5.20 × 10^−3^

DE = differentially expressed. CfmiRs = cell-free microRNAs. M =male. F = Female. FC = fold-change.

cancers-12-01692-t003_Table 3

###### 

CfmiRs that are commonly DE in male (M) versus female (F) in both serum and plasma of normal donors' samples.

  ---------------------------------------------------------------------------------
  Probe          FC Plasma M vs. F   Adjusted\       FC Serum M vs. F   Adjusted\
                                     *p*-Value                          *p*-Value
  -------------- ------------------- --------------- ------------------ -----------
  miR-451a       2.29                2.94 × 10^−5^   1.41               0.047

  miR-150-5p     1.84                1.10 × 10^−3^   1.44               0.023

  miR-8071       1.64                3.80 × 10^−3^   1.45               0.003

  miR-363-3p     1.58                1.16 × 10^−2^   1.35               0.047

  miR-6852-3p    1.56                4.60 × 10^−3^   1.47               0.007

  miR-6870-3p    1.52                8.70 × 10^−3^   1.31               0.035

  miR-92b-3p     1.49                3.57 × 10^−2^   1.39               0.0387

  miR-764        1.48                4.70 × 10^−3^   1.26               0.044

  miR-339-3p     1.48                1.75 × 10^−2^   1.37               0.025

  miR-6825-3p    1.48                1.05 × 10^−2^   1.43               0.015

  miR-6085       1.47                1.17 × 10^−2^   1.38               0.015

  miR-6796-3p    1.45                1.90 × 10^−3^   1.24               0.046

  miR-3155b      1.42                2.10 × 10^−3^   1.28               0.015

  miR-6742-5p    1.42                7.00 × 10^−3^   1.29               0.018

  miR-4309       1.42                5.10 × 10^−3^   1.29               0.014

  miR-1233-3p    1.42                1.03 × 10^−2^   1.36               0.015

  miR-4793-5p    1.42                3.20 × 10^−3^   1.37               0.009

  miR-497-3p     1.41                7.00 × 10^−3^   1.32               0.014

  miR-6069       1.40                7.00 × 10^−3^   1.3                0.016

  miR-640        1.40                8.60 × 10^−3^   1.33               0.012

  miR-5694       1.39                9.80 × 10^−3^   1.24               0.039

  miR-193b-3p    1.39                1.99 × 10^−2^   1.28               0.011

  miR-3912-5p    1.39                2.50 × 10^−3^   1.31               0.011

  miR-4655-3p    1.38                4.40 × 10^−3^   1.21               0.039

  miR-4726-3p    1.37                2.00 × 10^−3^   1.29               0.010

  miR-6715b-3p   1.37                5.10 × 10^−3^   1.31               0.009

  miR-3912-3p    1.37                7.50 × 10^−3^   1.32               0.011

  miR-3124-3p    1.36                6.10 × 10^−3^   1.26               0.015

  miR-33b-5p     1.36                1.66 × 10^−2^   1.29               0.020

  miR-671-5p     1.36                1.63 × 10^−2^   1.31               0.039

  miR-5587-3p    1.35                1.16 × 10^−2^   1.26               0.027

  miR-541-3p     1.35                7.90 × 10^−3^   1.27               0.036

  let-7g-3p      1.35                7.00 × 10^−3^   1.3                0.011

  miR-4291       1.35                1.75 × 10^−2^   1.32               0.014

  miR-2115-5p    1.33                5.40 × 10^−3^   1.23               0.039

  miR-1307-5p    1.33                3.90 × 10^−2^   1.33               0.024

  miR-3157-5p    1.33                1.15 × 10^−2^   1.36               0.009

  miR-217        1.33                1.40 × 10^−2^   1.38               0.003

  miR-937-3p     1.32                6.50 × 10^−3^   1.2                0.040

  miR-187-5p     1.32                1.16 × 10^−2^   1.3                0.010

  miR-4690-5p    1.31                2.70 × 10^−2^   1.25               0.013

  miR-187-3p     1.31                1.50 × 10^−2^   1.33               0.01

  miR-3907       1.30                2.90 × 10^−3^   1.22               0.03

  miR-6789-3p    1.30                2.70 × 10^−3^   1.27               0.01

  miR-2115-3p    1.30                7.70 × 10^−3^   1.28               0.011

  miR-4279       1.30                2.73 × 10^−2^   1.29               0.014

  miR-3714       1.30                1.30 × 10^−2^   1.34               0.005

  miR-1909-5p    1.29                1.45 × 10^−2^   1.26               0.022

  miR-4537       1.29                7.00 × 10^−3^   1.27               0.011

  miR-3689d      1.27                1.65 × 10^−2^   1.31               0.007

  miR-935        1.22                3.85 × 10^−2^   1.23               0.015

  miR-4746-5p    1.21                4.53 × 10^−2^   1.38               0.003

  miR-1273h-5p   −1.51               3.56 × 10^−2^   −1.33              0.034
  ---------------------------------------------------------------------------------

CfmiRs = cell-free microRNAs. DE = differentially expressed. M = male. F = Female. FC = fold-change.

cancers-12-01692-t004_Table 4

###### 

Clinical demographics of melanoma brain metastasis (MBM) patients analyzed.

                                          MBM-01      MBM-02
  --------------------------------------- ----------- -----------
  Age at diagnosis, year, mean (SD)       49 (26)     55 (14)
  Age at MBM diagnosis, year, mean (SD)   52 (28)     60 (13)
  Gender                                              
  Male                                    24 (66.7)   14 (58.3)
  Female                                  12 (33.3)   10 (41.7)

MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. SD = standard desviation.
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###### 

CfmiRs that are commonly DE in MBM-01 and MBM-02 plasma samples compared to normal donors' samples not present in the MBM tissues.

  -------------------------------------------------------------------------
  Probe         FC MBM-01\   Adjusted\        FC MBM-02\   Adjusted\
                vs. Normal   *p*-Value        vs. Normal   *p*-Value
  ------------- ------------ ---------------- ------------ ----------------
  miR-6741-3p   6.46         7.65 × 10^−37^   3.02         6.24 × 10^−15^

  miR-6852-3p   5.34         2.41 × 10^−22^   4.9          7.63 × 10^−26^

  miR-4689      4.14         1.21 × 10^−27^   6.84         4.66 × 10^−41^

  miR-3943      3.56         6.57 × 10^−21^   3.01         2.44 × 10^−21^

  miR-541-3p    3.34         8.31 × 10^−18^   1.56         7.64 × 10^−4^

  miR-3157-5p   3.12         2.07 × 10^−17^   3.27         1.08 × 10^−24^

  miR-4784      2.44         1.27 × 10^−13^   1.73         3.33 × 10^−7^

  miR-4279      2.36         2.28 × 10^−9^    1.79         5.84 × 10^−6^

  miR-4664-3p   2.17         1.96 × 10^−10^   4.31         7.29 × 10^−24^

  miR-4291      1.93         1.26 × 10^−5^    2.63         2.68 × 10^−19^

  miR-3912-5p   1.88         7.34 × 10^−7^    1.71         1.14 × 10^−7^

  miR-5694      1.82         2.47 × 10^−4^    1.46         6.00 × 10^−3^

  miR-3912-3p   1.79         1.35 × 10^−5^    1.57         4.39 × 10^−5^

  miR-670-3p    1.78         3.53 × 10^−5^    2.66         3.32 × 10^−22^

  miR-4665-5p   1.68         2.79 × 10^−4^    5.89         2.77 × 10^−23^

  miR-3937      1.67         1.10 × 10^−3^    2.98         3.76 × 10^−8^
  -------------------------------------------------------------------------

DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis. FC = fold-change.
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###### 

Statistics of PCA analysis of [Figure 3](#cancers-12-01692-f003){ref-type="fig"}B.

        MBM-01 Versus Normal Plasma   MBM-02 Versus Normal Plasma                           
  ----- ----------------------------- ----------------------------- ------- ------- ------- -------
  PC1   4.906                         0.310                         0.310   7.011   0.457   0.457
  PC2   4.383                         0.248                         0.558   4.782   0.213   0.670
  PC3   3.438                         0.152                         0.711   3.676   0.126   0.795
  PC4   2.452                         0.078                         0.788   2.458   0.056   0.851
  PC5   1.686                         0.037                         0.825   2.061   0.039   0.891

PCA = principal components analysis. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. PC = principal components.

cancers-12-01692-t007_Table 7

###### 

DE cfmiRs in MBM-01 and MBM-02 vs. normal donors' plasma that were also detected in MBM tissues. Cluster 1 (**A**), 2 (**B**), and 3 (**C**) ([Figure 3](#cancers-12-01692-f003){ref-type="fig"}C).

  -------------------------------------------------------------------------------------------------------------
  \(A\) Cluster 1                                                                   
  ------------------- ------------------------------ ------------------------------ ---------------------------
  miR-100-5p          150                            79                             98

  miR-125b-5p         235                            134                            126

  miR-181a-5p         1499                           842                            969

  miR-181b-5p         191                            113                            119

  miR-320b            4407                           2417                           3146

  miR-320d            2445                           1617                           1685

  miR-338-3p          224                            130                            112

  miR-342-3p          413                            227                            285

  miR-378a-3p         210                            139                            126

  miR-378f            136                            91                             82

  miR-378g            181                            130                            118

  miR-378i            217                            152                            133

  miR-4461            3221                           1837                           1113

  miR-6126            108,094                        78,636                         79,367

  miR-99a-5p          381                            146                            195

  miR-99b-5p          267                            171                            121

  **(B) Cluster 2**                                                                 

  **Probe**           **Mean Normalized**\           **Mean Normalized**\           **Mean Normalized**\
                      **Expression MBM-01 Plasma**   **Expression MBM-02 Plasma**   **Expression MBM Tissue**

  miR-1228-3p         92                             127                            171

  miR-1233-3p         234                            997                            1573

  miR-1307-3p         1067                           1554                           2763

  miR-1307-5p         787                            2465                           1792

  miR-143-5p          90                             114                            239

  miR-187-3p          135                            185                            282

  miR-339-3p          289                            4295                           1437

  miR-4667-5p         88                             160                            237

  miR-671-5p          162                            1274                           539

  miR-6789-3p         100                            147                            178

  miR-6796-3p         283                            681                            1513

  miR-6825-3p         173                            438                            586

  miR-6892-3p         409                            514                            808

  **(C) Cluster 3**                                                                 

  **Probe**           **Mean Normalized**\           **Mean Normalized**\           **Mean Normalized**\
                      **Expression MBM-01 Plasma**   **Expression MBM-02 Plasma**   **Expression MBM Tissue**

  miR-1207-5p         478                            759                            1354

  miR-1225-3p         188                            462                            609

  miR-1273a           109                            208                            308

  miR-1273c           171                            243                            357

  miR-1273e           428                            1248                           1914

  miR-1273g-5p        96                             129                            176

  miR-1299            109                            342                            318

  miR-3135a           81                             126                            216

  miR-3674            88                             178                            224

  miR-548d-5p         144                            248                            337

  miR-5585-3p         1372                           2369                           3112

  miR-574-5p          1632                           4042                           7203

  miR-6775-5p         143                            263                            279
  -------------------------------------------------------------------------------------------------------------

DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis.
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###### 

29 DE cfmiRs in MBM patients' plasma.

  Probe          FC MBM-01 vs. Normal   Adjusted *p*-Value   FC MBM-02 vs. Normal   Adjusted *p*-Value
  -------------- ---------------------- -------------------- ---------------------- --------------------
  miR-3937       1.67                   1.10 × 10^−3^        2.98                   2.09 × 10^−9^
  miR-1299       2.25                   1.07 × 10^−4^        2.95                   2.54 × 10^−10^
  miR-1273e      3.36                   2.30 × 10^−10^       2.79                   1.13 × 10^−12^
  miR-670-3p     1.78                   3.53 × 10^−5^        2.66                   2.96 × 10^−24^
  miR-1225-3p    2.55                   2.52 × 10^−10^       2.42                   3.85 × 10^−16^
  miR-574-5p     3.27                   2.52 × 10^−9^        2.36                   3.05 × 10^−7^
  miR-6780b-5p   1.90                   1.20 × 10^−3^        2.01                   6.58 × 10^−7^
  miR-3674       1.96                   5.90 × 10^−3^        1.95                   3.72 × 10^−4^
  miR-7111-5p    1.69                   6.50 × 10^−3^        1.89                   1.30 × 10^−6^
  miR-1273a      2.22                   7.15 × 10^−6^        1.85                   1.06 × 10^−4^
  miR-6877-5p    1.53                   2.92 × 10^−2^        1.84                   2.85 × 10^−5^
  miR-6775-5p    1.57                   3.50 × 10^−3^        1.81                   2.34 × 10^−6^
  miR-4279       2.36                   2.28 × 10^−9^        1.79                   7.18 × 10^−7^
  miR-5585-3p    1.77                   5.80 × 10^−3^        1.69                   3.48 × 10^−4^
  miR-548d-5p    1.81                   1.29 × 10^−2^        1.66                   7.80 × 10^−3^
  miR-7114-3p    1.88                   1.70 × 10^−6^        1.65                   2.27 × 10^−8^
  miR-1207-5p    2.23                   1.83 × 10^−7^        1.58                   1.71 × 10^−5^
  miR-3135a      2.12                   1.08 × 10^−5^        1.55                   6.26 × 10^−4^
  miR-6789-3p    1.44                   2.20 × 10^−3^        1.46                   1.23 × 10^−5^
  miR-1273c      1.67                   6.20 × 10^−3^        1.41                   1.63 × 10^−2^
  miR-1228-3p    1.50                   2.80 × 10^−3^        1.38                   5.43 × 10^−4^
  miR-1273g-5p   1.48                   2.29 × 10^−2^        1.35                   1.77 × 10^−2^
  miR-143-5p     2.12                   5.05 × 10^−11^       1.26                   4.60 × 10^−3^
  miR-6795-3p    −1.31                  1.43 × 10^−2^        −1.26                  7.06 × 10^−4^
  miR-6126       --1.63                 2.06 × 10^−2^        −1.36                  1.90 × 10^−2^
  miR-920        --1.64                 1.51 × 10^−8^        −1.42                  1.18 × 10^−4^
  miR-378f       --2.02                 4.64 × 10^−10^       −1.5                   1.53 × 10^−5^
  miR-3663-5p    --2.33                 4.44 × 10^−12^       −1.7                   2.23 × 10^−5^
  miR-3184-3p    −1430.32               1.02 × 10^−105^      −2.07                  2.78 × 10^−11^

DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis. FC = fold-change.
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###### 

Clinical pathological information for metastatic melanoma patients receiving CII analyzed for cfmiRs in plasma and urine samples.

                         Plasma (*n* = 20)   Urine (*n* = 14)   Paired Plasma and Urine (*n* = 11)
  ---------------------- ------------------- ------------------ ------------------------------------
  Age, year, mean (SD)   61.8 (21.1)         59.7 (24.9)        55 (13)
  Gender                                                        
  Male                   13 (66.7)           9 (64.3)           6 (54.5)
  Female                 7 (33.3)            5 (35.4)           5 (45.5)
  AJCC 8th stages                                               
  III b/c                3 (15)              4 (28.6)           2 (18.2)
  IV b/c/d               17 (85)             10 (71.4)          9 (81.8)
  *BRAF* mutations                                              
  Positive               12 (60)             9 (64.3)           7 (63.6)
  Negative               8 (40)              5 (35.7)           4 (36.4)
  Number of metastasis                                          
  1                      17 (85)             13 (92.9)          10 (85)
  2--3                   3 (15)              1 (7.1)            1 (15)

CII = checkpoint immune inhibitor. Cell-free microRNAs = cfmiRs. AJCC 8th stages at the start of the specific CII. SD = standard deviation.
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###### 

CfmiRs that were DE expressed in MBM-01 and MBM-02 cohorts that were also detected in pre- and post-treatment samples of metastatic melanoma patients receiving CII.

  Probe         FC MBM-01 vs. Normal   FC MBM-02 vs. Normal   FC MBM vs. LuBM   FC MBM vs. BCBM   FC MBM vs. GBM   FC Pre-CII vs. Normal   FC Post-CII vs. Normal
  ------------- ---------------------- ---------------------- ----------------- ----------------- ---------------- ----------------------- ------------------------
  miR-3184-3p   −2.07                  −1430.32               NDE               NDE               NDE              −2669.64                −3258.79
  miR-143-5p    1.26                   2.12                   NDE               NDE               NDE              1.81                    2.96
  miR-6789-3p   1.46                   1.44                   NDE               NDE               NDE              1.6                     2.94
  miR-1207-5p   1.58                   2.23                   NDE               NDE               NDE              1.54                    1.62
  miR-7114-3p   1.65                   1.88                   NDE               NDE               NDE              3.07                    5
  miR-4279      1.79                   2.36                   NDE               NDE               NDE              2.87                    4.74
  miR-1225-3p   2.42                   2.55                   NDE               NDE               NDE              1.4                     2.01
  miR-670-3p    2.66                   1.78                   NDE               NDE               NDE              1.45                    1.75

DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort. CII = checkpoint immune inhibitor. MBM = Melanoma brain metastasis. FC = fold-change. LuBM = lung brain metastasis. BCBM = breast cancer brain metastasis. GBM = glioblastoma. NDE = not detected as DE in the comparison.
